A prospective, multicenter, randomised, double-blind, placebo-controlled, phase 3 study to compare the efficacy and the safety of masitinib versus placebo in the treatment of patients with severe uncontrolled asthma and elevated eosinophil levels
Phase of Trial: Phase III
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Masitinib (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AB Science
- 31 Aug 2017 According to an AB Science media release, the first patient has been recruited in this trial.
- 31 Aug 2017 According to an AB Science media release, status changed from not yet recruiting to recruiting.
- 05 Jun 2017 New trial record